Bruce Cheson, MD
Enriched profileHematologist/Oncologist, The Center for Cancer and Blood Disorders · The Center for Cancer and Blood Disorders
Bruce Cheson is Hematologist/Oncologist, The Center for Cancer and Blood Disorders at The Center for Cancer and Blood Disorders. OpenAlex indexes 655 publications with 49,627 citations (h-index 89); ClinicalTrials.gov lists 5 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Bruce Cheson, MD, is Hematologist/Oncologist, The Center for Cancer and Blood Disorders. The public record shows 655 publications with 49,627 citations (h-index 89), centered on Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Lung Cancer Treatments and Mutations. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 36 companies.
- Most recent indexed publication: 2024 · JCO oncology practice
- Top research focus: Lymphoma Diagnosis and Treatment
- 5 registered trials on ClinicalTrials.gov
- Open Payments reporting from 36 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 10 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 276.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma
Sponsor: Academic and Community Cancer Research United
- Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Sponsor: Georgetown University
Industry payments
Updated 27 Aug 2026
36 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Geron CorporationProgram year20252 payments
- GlaxoSmithKline, LLC.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor100%Brukinsa37%Imbruvica32%Calquence31%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
69 congress contributions (2004–2025) across ASCO, ASH, ESMO per OpenAlex. The most recent:
- The efficacy and safety of pirtobrutinib in patients with CLL/SLL: A phase 2 dose optimization trial in progress
ASH Annual Meeting
ASH2025Co-author - Brentuximab Vedotin (BV) and Nivolumab (nivo) for Untreated Patients with Hodgkin Lymphoma (HL): Long-Term Results
ASH Annual Meeting
ASH2024Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Current Approaches and Novel Agents in the Treatment of Chronic Lymphocytic Leukemia.
JCO oncology practice
Review2024 - Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance).
Journal of clinical oncology
Article2023 - Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study.
Clinical cancer research
Clinical Trial2022
Most-cited works
by citation count (OpenAlex)- 01
- 02Revised Response Criteria for Malignant LymphomaArticle4,455 citations2007
- 03
- 04
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/bruce-cheson-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
lymphoma.org/wp-content/uploads/2021/04/LRF-Scientific-Advisory-Board-2021.pdf
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lymphoma.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Tufts University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ccbdmd.com ↗ - Board Certified
Hematology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ccbdmd.com ↗ - Board Certified
Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ccbdmd.com ↗ - Internal Medicine residency
University of Virginia Hospitals
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aol.amegroups.org ↗ - Hematology fellowship
New England Medical Center Hospital (now Tufts Medical Center)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aol.amegroups.org ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →eventscribe.net ↗
- Founding/Former Editor-in-Chief
Annals of Lymphoma (current masthead lists Mark Roschewski, MD as Editor-in-Chief)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aol.amegroups.org ↗ - Former Editor-in-Chief
Clinical Lymphoma, Myeloma & Leukemia
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →expertperspectives.com ↗
Awards & honors
honors on the public record- Elected Fellow
American Association for the Advancement of Science (AAAS)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →research.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →eventscribe.net ↗
- Fellow
American College of Physicians (FACP)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →expertperspectives.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pub.orcid.org ↗
- Former Head
Medicine Section, Cancer Therapy Evaluation Program (CTEP), National Cancer Institute
2002provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aol.amegroups.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aol.amegroups.org ↗
Media & interviews
press, podcasts and appearances- Guest
ASH 2016 Annual Meeting video interview on non-Hodgkin lymphoma treatment landscape and GADOLIN study results
2016provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - Guest
"Between the Lines" podcast (CancerNetwork) discussing tazemetostat in relapsed/refractory follicular lymphoma
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancernetwork.com ↗ - Featured expert
"Understanding Diffuse Large B-Cell Lymphoma with Bruce Cheson, MD" video
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Seth Steinberg, PhD
National Cancer Institute (NCI)
Gilles Salles
Memorial Sloan Kettering Cancer Center
Wyndham Wilson, MD
National Cancer Institute (NCI)
Julie Vose, MD
University of Nebraska Medical Center